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Studies of traumatic brain injury from all causes have found evidence of chronic hypopitu-
itarism, deﬁned by deﬁcient production of one or more pituitary hormones at least 1 year
after injury, in 25–50% of cases. Most studies found the occurrence of posttraumatic
hypopituitarism (PTHP) to be unrelated to injury severity. Growth hormone deﬁciency (GHD)
and hypogonadism were reported most frequently. Hypopituitarism, and in particular adult
GHD, is associatedwith symptoms that resemble those of PTSD, including fatigue, anxiety,
depression, irritability, insomnia, sexual dysfunction, cognitive deﬁciencies, and decreased
quality of life. However, the prevalence of PTHP after blast-related mild TBI (mTBI), an
extremely common injury in modern military operations, has not been characterized. We
measured concentrations of 12 pituitary and target-organ hormones in two groups of male
US Veterans of combat in Iraq or Afghanistan. One group consisted of participants with
blast-related mTBI whose last blast exposure was at least 1 year prior to the study. The
other consisted of Veterans with similar military deployment histories but without blast
exposure. Eleven of 26, or 42% of participants with blast concussions were found to have
abnormal hormone levels in one or more pituitary axes, a prevalence similar to that found
in other forms ofTBI. Five members of the mTBI group were found with markedly low age-
adjusted insulin-like growth factor-I (IGF-I) levels indicative of probable GHD, and three had
testosterone and gonadotropin concentrations consistent with hypogonadism. If symp-
toms characteristic of both PTHP and PTSD can be linked to pituitary dysfunction, they
may be amenable to treatment with hormone replacement. Routine screening for chronic
hypopituitarism after blast concussion shows promise for appropriately directing diagnos-
tic and therapeutic decisions that otherwise may remain unconsidered and for markedly
facilitating recovery and rehabilitation.
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INTRODUCTION
Recent studies investigating chronic pituitary dysfunction result-
ing from TBI have reported a prevalence of posttraumatic hypopi-
tuitarism (PTHP) ranging from 5 to 95% with a median of 35%,
the variation being primarily due to differences in screening cri-
teria (Bavisetty et al., 2008; Srinivasan et al., 2009; Berg et al.,
2010; Englander et al., 2010; High et al., 2010; Kokshoorn et al.,
2010, 2011; Krahulik et al., 2010; Park et al., 2010; Pavlovic et al.,
2010; Reimunde et al., 2011; Schneider et al., 2011). Pituitary
hormone disorders are frequently among the immediate conse-
quences of TBI; some resolve during the following months while a
smaller proportion of new dysfunctions emerge (Agha et al., 2005;
Aimaretti et al., 2005; Schneider et al., 2006, 2011; Tanriverdi et al.,
2006,2008b;Klose et al., 2007;Krahulik et al., 2010). By∼6months
subsequent to TBI, the pattern of pituitary deﬁcits is considered
to be relatively permanent.
The risk factors and the mechanisms, other than imme-
diate trauma-induced tissue damage and subsequent edema,
for chronic hypothalamo-pituitary dysfunction due to TBI are
unclear. Roles for polymorphisms in apolipoprotein E geno-
type (APOE), inﬂammatory processes – both systemic and
neural, and anti-hypothalamic (AHAs) and anti-pituitary anti-
bodies (APAs) have been proposed, and each has empirical
support.
There is evidence that the apolipoprotein E (APOE) ε3/ε3 geno-
type may be associated with a reduced risk of TBI-related hypopi-
tuitarism. APOE ε3 is the most common of the three alleles and
is found in more than half of the general population. The ε2 and
ε4 alleles have been associated with altered risks for Alzheimer’s
disease, hyperlipoproteinemia, and atherosclerosis. Pituitary dys-
function in patientswithTBI has been found to be signiﬁcantly less
prevalent in individuals with the APOE ε3/ε3 genotype (17.7%)
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than in patients with other genotypes (41.9%; p = 0.01; Tanriverdi
et al., 2008a).
Evidence for the involvement of APAs and/or AHAs in the
development of chronic PTHP comes from two studies. APAs
were detected in 44.8% of patients who had completed a 3-year-
follow-up after TBI and in none of the healthy control subjects,
and the prevalence of hypopituitarism was signiﬁcantly higher
in APA-positive (46.2%) than APA-negative TBI patients (12.5%;
p = 0.04; Tanriverdi et al., 2008b). In another study of active and
retired boxers, AHAs were detected in 21.3% and APAs in 22.9%
of boxers, whereas no evidence of APAs or AHAs was found in
control subjects (Tanriverdi et al., 2010a).
It is well established that TBI results in the acute induction of
both neural and systemic inﬂammatory responses and consequent
anti-inﬂammatory counter-responses (Lu et al., 2009; Ziebell and
Morganti-Kossmann, 2010). In addition, animal studies provide
evidence of the development of a chronic inﬂammatory state after
TBI. Threemonths aftermoderate focal brain injury in rats, persis-
tent major histocompatibility complex (MHC)-II up-regulation,
mononuclear phagocytosis, and elevated interleukin-1β (IL-1β)
and tumor necrosis factor-α (TNF-α) synthesis were observed in
large areas of the ipsilateral hemisphere (Holmin and Mathiesen,
1999). In another study, 2months after cortical contusion injury to
the medial frontal cortex of rats, IL-1β was signiﬁcantly increased
in the cortex and hypothalamus compared with a sham–trauma
group, and glial ﬁbrillary acidic protein (GFAP) was elevated in
the cortex, hypothalamus, and anterior pituitary of the TBI group
(Kasturi and Stein, 2009).
In general, the frequency of occurrence of pituitary hormone
abnormalities has not been found to be related to the severity of the
trauma (Lieberman et al., 2001; Agha et al., 2004a; Aimaretti et al.,
2004,2005;Bondanelli et al., 2004; Schneider et al., 2006;Park et al.,
2010; Kokshoorn et al., 2011), although there have been reports
of a positive relationship (Kelly et al., 2000; Klose et al., 2007). Of
the traumatic brain injuries sustained by∼1.7 million Americans
annually (Faul et al., 2010), 75% are considered mild TBI (mTBI;
National Center for Injury Prevention and Control, 2003).
Mild TBI is deﬁned by theAmericanCongress of Rehabilitation
Medicine (ACRM) as a head trauma resulting in any one of the fol-
lowing: loss of consciousness (LOC) for 30min or less, alteration
of mental state for up to 24 h (being dazed, confused, disoriented,
etc.), or loss of memory for events immediately before or after the
trauma (American Congress of Rehabilitation Medicine, 1993).
The terms mTBI and concussion are frequently used interchange-
ably (National Center for Injury Prevention and Control, 2003;
Department of Veterans Affairs/Department of Defense, 2009).
Mild TBI-related chronic pituitary dysfunction has been
reported in boxers and kick boxers subjected to repetitive head
injuries. In a preliminary study, 45% of professional boxers were
found with apparent growth hormone deﬁciency (GHD), but no
other pituitary hormone deﬁciencies were observed (Kelestimur
et al., 2004). In a larger study of active and retired boxers 18% had
pituitary hormone deﬁciencies in one or more axes (Tanriverdi
et al., 2008c). An investigation of pituitary dysfunction in ama-
teur kick boxers revealed GH and/or adrenocorticotropin (ACTH)
deﬁciencies in 27.3% of the athletes (Tanriverdi et al., 2007).
In 2010, the injuries in 80% of over 30,000 U.S. military ser-
vice members medically diagnosed with TBI were classiﬁed as
mTBI (Military Health System, 2011), and mTBI sustained from
explosive blasts is one of the most common combat injuries result-
ing from deployment to Iraq or Afghanistan. About 10–20% of
returnees report having experienced at least one blast concussion
(Tanielian et al., 2008; Terrio et al., 2009).
The extensive documentation of the high prevalence of hypopi-
tuitarism after TBI from all causes and the absence of any pub-
lished studies of the frequency of PTHP after blast-related mTBI
provided the rationale for this investigation of hypopituitarism
in U.S. Veterans of combat in Iraq and/or Afghanistan who have
experienced at least one blast concussion.
MATERIALS AND METHODS
PARTICIPANTS AND SAMPLE ACQUISITION
The VA Puget Sound Health Care System (VAPSHCS) Institu-
tional Review Board and the U.S. Army Medical Research and
Materiel Command (USAMRMC) Ofﬁce of Research Protections
(ORP) Human Research Protection Ofﬁce (HRPO) approved the
subject protocol with a waiver of informed consent. All plasma
and serum samples, demographic, and blast exposure data were
obtained from an established biorepository entitled “Alzheimer’s
Disease Research Center (ADRC) Participant Registry and Sample
Repository.” All subjects whose samples were utilized had con-
sented to have their samples and data used in future research of
this type.
The mTBI Veteran participants (T group) whose samples were
obtained from the repository were a convenience sample of 26
male Veterans recruited from VAPSHCS, all of whom had doc-
umented hazardous duty experience in Iraq and/or Afghanistan
with the U.S. Armed Forces and had reported experiencing at least
one blast exposure in the war zone that resulted in acute mTBI as
deﬁned by ACRM criteria (American Congress of Rehabilitation
Medicine, 1993) except that Glasgow Coma Scale scores were not
obtained in the combat setting. Samples from the repository were
also collected from seven maleVeterans who had been deployed to
Iraq and/orAfghanistanbutwhohadnot been exposed toblast and
had no history of TBI. These individuals made up the deployment
control (DC) group.
Additional samples from the repository which were used to
establish normal hormonal reference ranges had been collected
from 59 cognitively normal male community volunteers recruited
from theADRC,all of whomweremedically healthy andhadMini-
Mental State Examination scores of 29.4± 1.0 (mean± SEM;
range 27–30); Clinical Dementia Rating scores of zero; no evi-
dence or history of cognitive or functional decline; and no history
of blast exposure or head injury. These samples were used only for
the establishment of normative hormone concentrations with our
assay methods. Resting blood samples had been collected from all
participants between 9:00 and 10:00 a.m., at least 30min after the
insertion of an intravenous catheter in an antecubital vein.
None of the Veteran or community control participants had
a history of blast exposure, head injury with LOC greater
than 30min; penetrating head wound; seizure disorder; insulin-
dependent diabetes; current or past DSM-IV diagnoses of schiz-
ophrenia, other psychotic disorders, bipolar disorder, or demen-
tia; or a DSM-IV diagnosis of alcohol or other substance abuse
or dependence within the previous 3months. Participants using
medications likely to affect brain function, such as opioids,
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benzodiazepines, or anti-depressants, were asked not to take those
medications for 24 h prior to blood sampling.
BLAST EXPOSURE ASSESSMENT
Blast exposure and mTBI histories had been obtained from mTBI
Veteran participants during a clinical interview in which speciﬁc
inquiries were made regarding total number of blast exposures
accompanied by acute symptoms of TBI and/or LOC in Iraq
and/or Afghanistan and lifetime history of non-blast exposure
head injuries accompanied by acute symptoms of TBI and/or LOC
(e.g., sports or motor vehicle accident-related concussion).
NEUROLOGICAL ASSESSMENT
All subjects underwent a full neurological examination, includ-
ing the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) motor
section (Martínez-Martín et al., 1994). Olfactory function was
assessed using the Brief Smell Identiﬁcation Test (B-SIT; Doty
et al., 1996).
HORMONE MEASUREMENT
Blood samples for the measurement of plasma hormone concen-
trations were collected between 9:00 and 10:00 a.m. in chilled
tubes containing ethylenediaminetetraacetic acid (EDTA), placed
on ice, and centrifuged at 4˚C prior to removal of the plasma frac-
tion. Blood samples for measurement of serum hormones were
collected in serum-separator tubes, allowed to clot at room tem-
perature for 10min, and centrifuged to isolate serum. Serum and
plasma samples were aliquoted and stored at −70˚C. Twelve pitu-
itary or target-organ hormones were measured in these samples.
The type, source, and performance characteristics of the assay
kits used for the measurement of hormone concentrations in
serum and plasma are shown in Table 1. ACTH, cortisol, thyroid-
stimulating hormone (TSH), oxytocin, and vasopressin concen-
trations were determined in plasma; free thyroxine, luteinizing
hormone (LH), follicle-stimulating hormone (FSH), total testos-
terone, insulin-like growth factor-I (IGF-I), growth hormone, and
prolactin were measured in serum.
CLINICAL LAB DATA
Measurements of plasma and urine osmolality were not available
but urine speciﬁc gravity was measured and used as a criterion to
determine functional vasopressin insufﬁciency.
STATISTICAL ANALYSIS AND CRITERIA FOR PITUITARY DEFICIENCIES
The criteria for PTHP,derived using hormonemeasurements from
the 59 community control participants are shown in Table 2. For
each hormone, age-adjusted percentiles based on the lognormal
distribution from community control participants were estimated
and dysfunction in each of seven hormonal axes was deﬁned (R
Development Core Team, 2011). Hypopituitarism was deﬁned as a
dysfunction in at least one of these seven axes. These criteria were
Table 1 | Sources and characteristics of hormone assay kits.
Assay Kit name Manufacturer Location
ACTH ACTH Immunoradiometric (IRMA) Assay Scantibodies Laboratory Santee, CA, USA
Cortisol GammaCoat™Cortisol 125I RIA Diasorin Stillwater, MN, USA
FSH DELPHIA hFSH Perkin Elmer Waltham, MA, USA
GH hGH-ELISA, Ultra-Sensitive DSL Webster, TX, USA
IGF-I IGF-I RIA IBL America Minneapolis, MN, USA
LH ImmuChem™CoatedTube LH 125I RIA MP Biomedicals Costa Mesa, CA, USA
Oxytocin Oxytocin EIA Kit – Extraction-free Peninsula Labs/Bachem San Carlos, CA, USA
Prolactin ImmuChem™CoatedTube Prolactin 125I IRMA MP Biomedicals Costa Mesa, CA, USA
Testosterone Total Testosterone Siemens Diagnostics Los Angeles, CA, USA
Thyroxine FreeThyroxine (FT4) Microplate EIA MP Biomedicals Costa Mesa, CA, USA
TSH ImmuChem™CoatedTubeTSH 125I IRMA MP Biomedicals Costa Mesa, CA, USA
Vasopressin Vasopressin Direct RIA ALPCO Salem, NH, USA
Hormones Assay type Sample type Assay size Sample size Assay range Sensitivity Intra-assay CV Inter-assay CV
ACTH IRMA Plasma 100Tubes 200μl 9–1693 pg/ml <1.0 pg/ml 4.05 6.66
Cortisol RIA Plasma 100Tubes 10μl 1–60μg/dl 0.21μg/dl 7.03 9.20
FSH Fluoroimmunoassay Serum 96Wells 25μl 0.98–256U/l 0.05U/l 2.33 1.87
GH EIA Serum 96Wells 100μl 4.5–500 pg/ml 0.66 pg/ml 6.00 5.40
IGF-1 RIA Serum 100Tubes 100μl 0.16–10.0 ng/ml 0.02 ng/ml 2.97 10.30
LH RIA Serum 100Tubes 100μl 2.5–200mIU/ml 1.5mIU/ml 5.90 7.90
Oxytocin EIA Plasma 96Wells 50μl 0–630 pg/ml 6.5 pg/ml 9.36 13.67
Prolactin IRMA Serum 100Tubes 25μl 2.5–100 ng/ml 2.5 ng/ml 5.13 8.08
Testosterone Solid-phase RIA Serum 100Tubes 50μl 20–1600 ng/dl 4 ng/dl 3.40 7.90
Thyroxine EIA Serum 96Wells 50μl 0.45–7.6 ng/dl 0.05 ng/dl 6.83 6.47
TSH IRMA Plasma 100Tubes 200μl 0.2–50μIU/ml 0.04μIU/ml 4.10 5.23
Vasopressin RIA Plasma 100Tubes 400μl 1.25–80 pg/ml 0.1 pg/ml 6.00 9.90
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Table 2 | Screening criteria for identifying abnormal circulating hormone levels.
Axis Criteria using lognormal distribution of community control reference sample
Adrenal insufﬁciency Cortisol<10th percentile (6.7μg/dl), and ACTH<10th percentile (18 pg/ml)
Thyroid deﬁciency FreeT-4<5th percentile (0.87 ng/dl), andTSH<50th percentile (2.39μIU/ml)
Hypogonadism Total testosterone<5th percentile (330 ng/dl) and either LH or FSH<10th percentile (2.3mIU/ml, 1.3U/l, respectively) OR
(total testosterone<5th percentile and prolactin>95th percentile (32 ng/ml)
Vasopressin abnormality Vasopressin>95th percentile (9.46 pg/ml) OR vasopressin<5th percentile (0.27 pg/ml) and urine speciﬁc gravity<1.003
Prolactin abnormality Prolactin>95th percentile (32.0 ng/ml) OR prolactin<5th percentile (6.7 ng/ml)
GH deﬁciency IGF-1< age-adjusted 10th percentile (SDS<−1.4)
Oxytocin deﬁciency Oxytocin<5th percentile (22.7 pg/ml)
Hypopituitarism Abnormalities in at least one of these 7 axes
modeled after those used in published studies of hypopituitarism
after TBI from all causes.
RESULTS
PLASMA/SERUM HORMONE SCREENING EVALUATIONS
Eleven of 26mTBI subjects (T), or 42%,were found to have abnor-
mal hormone values in at least one axis. As reported in earlier
studies of PTHP, deﬁciencies in the growth hormone-IGF-I and
pituitary–gonadal axes were observed most frequently (Bavisetty
et al., 2008; Dusick et al., 2008; Schneider et al., 2008; Englander
et al., 2010; Kokshoorn et al., 2010; Krahulik et al., 2010; Park et al.,
2010; Pavlovic et al., 2010; van der Eerden et al., 2010).
Markedly low IGF-I levels are strong indicators of adult GHD
(Juul et al., 1997; Hartman et al., 2002; Hadjadj et al., 2007; Ho,
2007; Prodam et al., 2008; Tanriverdi et al., 2011; Zgaljardic et al.,
2011). The red line in Figure 1 represents the cutoff level used to
deﬁne our criterion for subnormal IGF-I levels indicative of proba-
bleGHD.The cutoff level was deﬁned to be an IGF-I concentration
below the age-adjusted 10th percentile level [equivalent to an SD
score (SDS) below −1.4] of the community control reference sam-
ple (Figure 1; Table 2). Five Veteran participants with mTBI (T-4,
T-8, T-16, T-25, and T-28) were found to have serum IGF-I con-
centrations below this cutoff line. None of theVeteran participants
in theDC groupwere found to have subnormal age-adjusted IGF-I
levels (Figure 1).
Three participantswithmTBI (T-4,T-13, andT-28)were found
with abnormal hormonal proﬁles indicating probable hypogo-
nadism. The criteria were a total testosterone concentration less
than the 5th percentile of the reference sample together with an
LHor FSH level below the 10th percentile reference level (Figure 2;
Table 2). T-4 and T-28 also had the lowest two IGF-I levels among
the participants (T-4: 126 ng/ml, SDS=−2.325; T-28: 86 ng/ml,
SDS=−2.989). Elevated prolactin levels in conjunction with low
testosterone are also indicative of hypogonadism. A serum pro-
lactin concentration markedly higher than the 95th percentile of
the reference sample was found in serum from participant T-4. A
subnormal prolactin concentration (<5th percentile), also associ-
ated with sexual dysfunction, was measured in serum from T-13.
None of the Veterans in the DC group were found to have
hormone levels indicative of hypogonadism. One participant in
the DC group was found with a total testosterone concentration
below the 5th percentile reference standard and another had an LH
FIGURE 1 | IGF-I concentrations in serum from deployment control
(DC) participants (triangles) and participants with mTBI (T, circles).The
screening criterion for growth hormone deﬁciency was an IGF-I level below
the age-adjusted 10th percentile of IGF-I concentration (diagonal red line) in
the community control reference group. Serum IGF-I values of ﬁve Veterans
with mTBI fell below this cutoff line. None of the DC group met this
criterion.
concentration below the 10th LH percentile, but neither exhib-
ited the combined gonadotropin and testosterone deﬁciencies
consistent with hypogonadism.
None of the Veteran participants in either the T or DC
group exhibited abnormalities in the hypothalamic-pituitary–
adrenocortical or hypothalamic-pituitary–thyroid axis (Table 3).
The corticotrophs and thyrotrophs are located in the protected
median wedge of the anterior pituitary and are anatomically less
vulnerable to injury than gonadotropin- and GH-secreting cells.
This differential anatomical vulnerability correlates well with the
frequency of chronic hormonal abnormalities observed after TBI
(Bavisetty et al., 2008; Blair, 2010; Krahulik et al., 2010).
In addition to the ﬁndings of anterior pituitary hormone
abnormalities in six Veteran participants with mTBI, eight
instances of anomalous posterior pituitary hormone levels were
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FIGURE 2 | Serum LH (left) and testosterone (right) in the deployment
control (DC, triangles) and mTBI (T, circles) groups. Screening criteria for
hypogonadism: LH (or FSH) levels below the 10th percentile of the control
range together with testosterone below the 5th percentile (red lines). Green
circles mark data from 3T subjects falling below both cutoffs. No DC subjects
met both criteria.
found in six Veterans in the mTBI group, one of whom, T-28,
also had evidence of presumptive GHD and hypogonadism. The
plasma oxytocin concentrationwas unmeasurably low in this indi-
vidual (Table 3). None of theVeterans in the DC group were found
to have abnormal posterior pituitary hormone values.
Three additional participants from the mTBI group (T-10,
T-14, and T-22) also were found to have circulating oxytocin
concentrations below the reference sample’s 5th percentile level.
Two of these participants, T-10 and T-22, also met our crite-
ria for arginine vasopressin (AVP) deﬁciency: plasma vasopressin
concentration below the 5th percentile of the reference level in
combination with urine speciﬁc gravity less than 1.003. In addi-
tion, plasma vasopressin concentrations in participants T-2 and
T-12 were abnormally elevated above the 95th percentile of the
reference group.
DEMOGRAPHICS, DEPLOYMENT HISTORY, BLAST EXPOSURE, AND
MEDICATION USE
After completion of hormone measurement and identiﬁcation
of Veterans with apparent hypopituitarism, participants in the
T group were divided into two subgroups, based on the pres-
ence or absence of hormone abnormalities, for comparison of
demographic, deployment history, blast exposure, and medica-
tion use data with each other and with the DC group. The three
groups of Veteran participants did not differ in age, education, or
body mass index at the time of enrollment, and the two mTBI
subgroups did not differ signiﬁcantly from one another on any of
the measures of deployment history or blast exposure (Table 4).
CONCURRENT MEDICATIONS
Medications with potential neuroendocrine effects taken by mTBI
subjects found to have indications of hypopituitarism were opi-
ates (2/11), prazosin (2/11), selective serotonin reuptake inhibitors
(SSRIs; 4/11), serotonin and norepinephrine reuptake inhibitors
(SNRIs; 2/11), hypnotics (2/11), atypical antipsychotics (1/11),
calcium channel blockers for migraine (1/11), benzodiazepines
(1/11), and mirtazapine (1/11). Five subjects in this group were
not taking any neuroactive medications. Medications with poten-
tial neuroendocrine effects taken by mTBI subjects found to have
hormone levelswithin normal rangeswere opiates (1/15),prazosin
(4/15), SSRIs (3/15), SNRIs (2/15), mirtazapine (1/15), trazodone
(1/15), benzodiazepines (1/15), and disulﬁram (1/15). Nine sub-
jects in this group were not taking any neuroactive medications.
Medications with potential neuroendocrine effects taken by DC
subjects were opiates (1/7), SSRIs (1/7), and SNRIs (1/7). Five
subjects in this groupwerenot taking anyneuroactivemedications.
DISCUSSION
Our ﬁndings in this preliminary study support the hypothesis that
blast mTBI carries a risk of PTHP similar to that found in several
previous studies of hypopituitarism in the general population after
TBI from all causes. We have found that blood samples from 11 of
26,or 42%ofVeterans of combat in Iraq orAfghanistanhad abnor-
mal circulating hormone concentrations consistent with PTHP.
Five participants with blast mTBI exhibited evidence of anterior
pituitary dysfunction, ﬁve additional subjects had anomalous pos-
terior pituitary hormone levels, and the eleventhwas found to have
both anterior and posterior pituitary hormonal abnormalities. In
contrast, none of the seven Veterans of deployment to Iraq and/or
Afghanistan in the studywhodid not experience blast trauma – the
DC group – were found to have evidence of pituitary dysfunction.
As Kokshoorn et al. (2010) pointed out in their review of 14
investigations of PTHP conducted between 2000 and 2009, these
early studies used a broad variety of screening criteria that were
sometimes described in general terms rather than with speciﬁcally
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Table 3 | Plasma or serum hormone concentration for each participant.
Subject Age #BE ACTH
(pg/ml)
Cort
(μg/dl)
LH
(mIU/ml)
FSH
(U/l)
tTest
(ng/dl)
PRL
(ng/ml)
TSH
(μIU/ml)
fT-4
(ng/dl)
IGF-I
(ng/ml)
GH
(pg/ml)
AVP
(pg/ml)
OT
(pg/ml)
T-1 24 11 24 6.6 2.58 0.46 473 12.5 1.70 1.29 190 58 3.4 64
T-2 26 6 20 11.9 2.03 – 669 9.6 1.92 1.67 185 71 12.3 181
T-3 27 10 22 10.2 5.15 2.05 557 13.0 1.59 1.59 164 50 4.0 166
T-4 33 15 19 7.5 2.03 2.06 252 54.9 1.17 1.22 110 11 8.0 88
T-5 38 102 24 12.8 2.11 2.33 362 14.9 1.16 1.18 133 0 0.4 71
T-6 46 5 29 12.1 1.95 1.41 402 11.1 1.08 1.09 143 152 0.7 61
T-7 26 20 28 14.1 3.34 1.63 559 12.0 2.26 1.29 172 223 0.0 39
T-8 25 21 35 11.3 2.72 4.02 401 11.9 1.13 1.55 141 294 0.2 44
T-9 24 102 39 12.0 4.81 3.28 730 14.4 1.16 1.05 251 1288 8.0 52
T-10 26 20 30 9.6 1.97 2.43 520 12.3 2.41 1.39 230 68 0.2 22
T-11 28 9 31 10.2 1.64 2.38 382 9.2 1.30 1.22 182 0 1.1 36
T-12 27 15 27 9.9 7.27 5.70 715 13.0 1.57 1.38 198 60 12.0 55
T-13 31 7 40 7.8 1.92 1.18 253 6.3 2.24 1.14 187 0 6.4 50
T-14 30 6 36 8.8 2.66 2.51 390 12.0 3.75 1.13 151 310 0.5 19
T-15 27 11 16 7.4 2.27 3.56 377 10.1 1.40 1.14 168 42 4.4 85
T-16 28 66 25 11.7 2.64 4.01 380 21.5 0.65 1.52 126 0 0.9 190
T-17 25 18 26 11.2 9.32 3.00 465 17.1 1.26 1.25 197 0 4.8 151
T-18 24 7 30 14.2 3.65 2.21 556 12.2 1.27 1.30 179 60 4.3 32
T-19 30 1 32 18.6 5.44 3.01 457 11.7 1.55 1.13 190 66 0.0 46
T-20 28 3 17 25.0 6.65 3.91 309 10.4 0.79 1.31 210 1696 7.9 519
T-22 25 4 21 17.6 4.00 4.48 588 12.8 1.09 1.24 227 110 0.0 21
T-23 29 52 11 8.7 2.52 2.55 554 8.9 1.34 1.35 166 95 4.0 199
T-25 25 12 8 7.7 2.24 4.34 463 7.2 1.42 1.23 146 813 2.1 25
T-26 26 11 9 6.8 5.94 1.14 488 8.4 0.81 1.18 185 42 0.9 457
T-27 43 5 29 7.5 2.52 3.89 263 7.1 0.60 1.04 126 13 2.6 50
T-28 41 12 15 11.1 2.11 2.64 264 15.3 1.22 1.11 86 375 8.4 0
Shaded values indicate hormone axis abnormalities as deﬁned in Table 2. #BE, number of self-reported blast exposures meeting ACRM criteria for mTBI during
military career; ACTH, adrenocorticotropin; Cort, cortisol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; tTest, total testosterone; PRL, prolactin; TSH,
thyroid-stimulating hormone; fT-4, free thyroxine; IGF-I, insulin-like growth factor-I; GH, growth hormone; AVP, vasopressin; OT, oxytocin.
deﬁned cutoffs. We attempted to use relatively conservative and
explicitly deﬁned criteria based on the distribution of speciﬁc hor-
mone concentrations measured in a reference population. We did
not employ provocative testing but used criteria based on mea-
surement of both pituitary hormones and their target-organ hor-
moneswhenpossible, e.g., a combinationof measurements of total
testosterone, LH, FSH, and prolactin to screen for hypogonadism.
It should be cautioned that the determinations of basal hor-
mone concentrations, such as those made in this study, are meant
to be screening tools, and are not intended to be, nor should they
be interpreted to be, diagnostic in the absence of clinical assess-
ment. Measurement of basal circulating hormone concentrations
is generally considered an appropriate screening tool for provi-
sional identiﬁcation of deﬁcient thyroid function, hypogonadism,
and prolactin and oxytocin deﬁciencies. Diagnosis of signiﬁcant
abnormalities of vasopressin secretion normally require conﬁrma-
tion by measures of plasma and/or urine osmolality, urine speciﬁc
gravity (UGS), and/or the administration of a water deprivation
test. Although provocative testing is generally considered neces-
sary for diagnosis of sAI and GHD, measurement of basal cortisol
and IGF-I concentrations remain valuable screening tools to iden-
tify individuals most likely to beneﬁt from additional testing and
clinical referral. Evaluation of clinical signs and symptoms are
essential for deﬁnitive diagnoses in all cases.
Previous studies have found GHD to be the most prevalent
chronic endocrine consequence of TBI, and it carries with it a
potentially large range of symptoms. Provocative testing is con-
sidered to be a requisite for the reliable diagnosis of GHD because
serum GH concentrations measured in the morning are not valid
indicators of daily secretion or somatotroph function. GH secre-
tion occurs predominantly during sleep, and morning levels are
generally very lowbut punctuatedunpredictably by short secretory
bursts (Van Cauter et al., 1992). However, GH stimulates hepatic
production of IGF-I that provides a useful index of somatotroph
function. IGF-I concentrations have low diagnostic sensitivity for
identifying GHD but are highly speciﬁc. The presence of normal
IGF-I values cannot be used to exclude GDH because it is often
diagnosed in individualswith normal or even elevated IGF-I levels.
However, markedly low age-adjusted levels of IGF-I are strongly
indicative of GHD (Juul et al., 1997; Hadjadj et al., 2007; Ho, 2007;
Prodam et al., 2008; Tanriverdi et al., 2011; Zgaljardic et al., 2011).
Circulating IGF-I concentrations declinemarkedlywith increasing
age, and this decline must be taken into account when interpreting
them.
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Table 4 | Mean±SEM and (range) for demographic, deployment, and blast exposure data for each group of participants.
DC (n=7) mTBI without PTHP(n=15) mTBI with PTHP(n=11)
A. DEMOGRAPHICS
Age (years) 31.1±3.3 (23–47) 29.7±1.8 (24–46) 28.8±1.5 (25–41)
Education (years) 14.0±0.7 (12–17) 13.3±0.4 (11–16) 13.6±0.5 (12–16)
Marital status 3/7 Married, 4/7 single 7/15 Married, 4/15 single, 2/15
divorced, 2/15 unknown
7/11 Married, 1/11 single, 1/11
separated, 2/11 unknown
Body mass index (BMI) 28.5±2.1 (n =5)† 27.9±1.3 (n =14)† 29.0±1.3 (n =10)†
B. DEPLOYMENT HISTORY
Number of deployments 1.7±0.4 (1–3) 1.9±0.2 (1–4) 2.1±0.3 (1–3)
Time between ﬁrst and second
deployments (months)
14.3±7.0 (3.5–27.5) (n =3) 15.9±3.1 (4.0–39.5) (n =10) 15.4±2.4 (7.5–30.0) (n =8)
Time between second and third
deployments (months)
6.0±1.0 (5.0–7.0) (n =2) 8.0±2.0 (6–12) (n =3) 7.6±2.0 (3.0–12.5) (n =4)
Time between third and forth
deployments (months)
8.0±0.0 (n =1)
Total deployment time (months) 13.0±1.8 (7–21) 18.7±2.2 (7–37) 18.2±1.7 (11–27)
C. BLAST EXPOSURE
Deployment blast exposures meeting
ACRM criteria for mTBI
0 11.1±3.3 (1–52) 14.6±5.4 (4–66)
Blast exposures meeting ACRM criteria
during military career
0.3±0.3 (0–2) 24.5±8.7 (1–102) 16.7±5.2 (4–66)
Blast exposures with LOC 0 1.3±0.3 (0–4) 0.6±0.2 (0–2)
Lifetime events with LOC 0.1±0.1 (0–1) 3.1±0.7 (0–11) 1.3±0.4 (0–3)
Time since last blast exposure (months) 45.2±4.2 (14–66) 47.4±4.3 (20–67)
TheVeterans with blast mTBI (T group) were divided into two subgroups based upon the presence or absence of abnormal hormonal proﬁles suggesting PTHP. † BMIs
were not obtained for all participants.
Studies using receiver operating characteristic (ROC) analysis
to compare the diagnostic accuracy of IGF-I relative to diagnosis of
GHD based on provocative testing of GH secretion have reported
a diagnostic speciﬁcity of 100% with IGF-I SDS cutoffs of −1.3
(Corneli et al., 2007) or −1.7 (Maghnie et al., 2005).
The individuals classiﬁed here as having a high probability of
GHD all had values less than −1.4 SDs below the age-adjusted
means of the reference sample. The high speciﬁcity of IGF-I
measurements at this level assures a very low likelihood of false
positives in diagnosing GHD. However, in light of the low sensi-
tivity of IGF-I concentrations in predicting GHD, it is probable
that some Veteran participants with normal IGF-I levels may be
growth hormone deﬁcient.
The long-term sequelae of GHD in adults for health, quality
of life (QoL), and morbidity are multifaceted and complex. Low
GH secretion has been associated with behavioral symptoms and
deﬁcits in several cognitive domains (Popovic et al., 2004; Fall-
eti et al., 2006; Pavlovic et al., 2010). GHD also has signiﬁcant
deleterious effects on body composition and cardiovascular func-
tion. Adult GHD is associated with lipidemia, reduced lean body
mass, and increased adiposity. Even partial GHD in adult patients
is associated with adverse lipid proﬁles and early atherosclero-
sis (Colao et al., 2006a,b; Colao, 2008). Impairment in QoL is
also a prominent feature of adult GHD, especially in the areas of
energy and vitality (McGauley, 1989; Kelly et al., 2006; Bushnik
et al., 2007; Svensson et al., 2007; Bavisetty et al., 2008). Adult
GHD is also associated with reductions in muscle volume and
strength, decreased physical mobility, fatigue, sleep impairment,
social isolation, depression, lowered metabolic rate, low sexual
drive, and reduced aerobic capacity (Rosén et al., 1994; Mossberg
et al., 2008).
Many of the symptoms of GHD can be successfully ame-
liorated or reversed by growth hormone replacement therapy.
Five retrospective studies have shown that the risk of prema-
ture death from cardiovascular disease is elevated in patients with
GHD (Svensson et al., 2004a). The increased risk factors such as
adverse lipid proﬁles, increased blood pressure, abnormal body
composition, increased body weight, increased coagulability, and
increasedmarkers of inﬂammationhave all been shown to improve
with GH replacement (Svensson et al., 2004a, 2007; Götherström
et al., 2007a; Verhelst and Abs, 2009). GH replacement has been
found to be effective in reversing cognitive impairments in several
domains including simple motor speed, information processing
speed, episodic memory, mental ﬂexibility, verbal memory, and
executive functioning in patients after TBI (High et al., 2010;
Reimunde et al., 2011). GH replacement also normalizes muscle
strength and increases bone mineral density (Götherström et al.,
2007b, 2009), improves psychiatric functioning by ameliorating
depression, intensity of interpersonal sensitivity, hostility, para-
noid ideation, and anxiety (Maric et al., 2010), and improves QoL
(Svensson et al., 2004b, 2007; Kreitschmann-Andermahr et al.,
2008).
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Three of the Veteran participants in the T group met our crite-
ria for hypogonadism: a total testosterone concentration less than
the 5th percentile of the reference sample together with an LH or
FSH level below the 10th percentile reference level. In our very
small sample, the occurrence of hypogonadism was found to be
next highest in frequency to that of GHD, as was the case in sev-
eral of the studies of PTHP after TBI from all causes in the general
population (Bavisetty et al., 2008; Dusick et al., 2008; Krahulik
et al., 2010; Park et al., 2010; Tanriverdi et al., 2010b).
Hypogonadism has signiﬁcant deleterious consequences in
addition to its adverse effects on fertility, psychosexual function,
and general well being. Testosterone deﬁciency in males is asso-
ciated with decreased energy and motivation, muscle weakness,
reduced lean body mass, and impaired exercise tolerance (Agha
and Thompson, 2005). In addition, a recent large epidemiologi-
cal study has shown that untreated hypogonadism is associated
with premature mortality secondary to cardiovascular disease
(Tomlinson et al., 2001).
One mTBI participant, T-4,was found to have a highly elevated
concentration of prolactin, 2.5 times higher than the next high-
est concentration measured in the T group and more than four
times higher than the highest value in the DC group. Hyperpro-
lactinemia has been causally linked with hypogonadism, speciﬁ-
cally by reducing LH and FSH secretion, blocking LH stimulation
of testicular testosterone secretion, and producing oligospermia
by reducing FSH levels, resulting in hypoactive sexual desire and
erectile dysfunction.
Prolactin is the only anterior pituitary hormone that is under
predominantly inhibitory control. Its secretion is suppressed by
dopamine, and in the absence of this inhibition, prolactin is
released at high levels. Hyperprolactinemia frequently results from
the use of antipsychotic medications that act as antagonists at
dopamine D2 receptors (Holt, 2008; Inder and Castle, 2011).
Participant T-4 had been taking quetiapine, an atypical antipsy-
chotic with fast dissociation kinetics at the D2 receptor [released
from D2 within 12–24 h (Seeman, 2010)] that results only in low
and transient prolactin secretion (Carboni et al., 2011). It has not
generally been associated with hyperprolactinemia in clinical use
(Haddad and Wieck, 2004; Byerly et al., 2007; Bushe et al., 2010)
although a prevalence of 22% was found in one study (Mont-
gomery et al., 2004). It is often referred to as a dopamine-sparing
antipsychotic, and although it is much less potent in elevating
prolactin levels than several other antipsychotics (e.g., haloperidol
and risperidone), it may have prolactin-elevating effects in some
individuals, perhaps including participant T-4.
One of the Veterans with mTBI was found to have a subnor-
mal (less than 5th percentile) prolactin concentration. Hypopro-
lactinemia is rare in the general population, but it too has been
associated with sexual dysfunction, primarily arteriogenic erectile
dysfunction and premature ejaculation (Corona et al., 2009).
We found no evidence of dysfunction in the thyroid or adrenal
axes as a result of blast mTBI. Previous studies of pituitary deﬁ-
ciencies after TBI from all causes have generally reported a lower
prevalence of TSH and adrenocorticotropin (ACTH) deﬁciencies
than of GH or gonadotropin deﬁcits (Bavisetty et al., 2008; Blair,
2010; Krahulik et al., 2010). This pattern may be due in part to the
location of pituitary corticotrophs and thyrotrophs in the gland’s
protected median wedge and their blood supply via both the long
hypophysial portal vessels and the inferior hypophysial artery.GH-
secreting somatotrophs, on the other hand, are anatomically more
vulnerable to damage because of their location in the pituitary’s
exposed lateral wings and their primary dependence on vascular
input from the portal system alone. Gonadotrophs are distributed
throughout the anterior pituitary, and the cells in the lateral wings
are relatively vulnerable.
In addition to the six participants with hormonal levels con-
sistent with hypogonadism and/or GHD, six of the Veterans with
mTBI (including one with anterior pituitary hormonal abnor-
malities) exhibited abnormal plasma vasopressin and/or oxytocin
concentrations. Oxytocin concentrations below the 5th percentile
value of the community control groupwere observed in four of the
mTBI participants. Two of the four also exhibited indications of
vasopressin deﬁciency as deﬁned by vasopressin levels below the
5th percentile of the community reference group together with
urine speciﬁc gravity less than 1.003. The occurrence of deﬁcits
of both vasopressin and oxytocin in two participants suggests the
possibility of disruption of the pituitary stalk or hypothalamic
damage in these individuals. In addition, elevated plasma vaso-
pressin concentrations above the reference 95th percentile were
measured in two subjects.
In several studies, elevated cerebrospinal ﬂuid (CSF) or periph-
eral vasopressin concentrations have been associated with PTSD,
depression, schizophrenia, and other psychiatric disorders, but a
causal relationship has not been established (Purba et al., 1996; van
Londen et al., 1997;Coccaro et al., 1998;Merali et al., 2006; deKloet
et al., 2008; Goekoop et al., 2009; Heinrichs et al., 2009). In con-
trast, there is evidence fromboth animal andhuman studies for the
positive association of oxytocin levels with social bonding, attenu-
ation of stress responses in socially relevant challenges, mediation
of social support, and positive social interactions (Heinrichs et al.,
2009; Campbell, 2010).
Our ﬁnding of a high frequency of abnormal peripheral hor-
mone levels after blast mTBI in this preliminary study is consistent
with the investigations cited above, in which the prevalence of
pituitary dysfunction fell in the 30–60% range in 11 of 22 reports.
However, in general, those studies focused exclusively on anterior
pituitary dysfunction. Although few studies have investigated the
prevalence of chronic posterior pituitary hormonal abnormalities
after TBI, most (Agha et al., 2004b, 2005; Krahulik et al., 2010),
but not all (Bondanelli et al., 2004), found signiﬁcant evidence
of damage in that lobe as well. In this study we found signiﬁcant
anterior pituitary dysfunction in 23.1% of Veterans with mTBI
and abnormal posterior pituitary hormone levels in 23.1% of this
group as well. In contrast, the prevalence of hypopituitarism in
the general adult population ranges between 290 and 455 cases
per million (Regal et al., 2001).
The only other ongoing study of hypopituitarism after blast
mTBI of which we are aware recently reported preliminary results
based on two retrospective chart reviews. Of 147 Marines with
blast-related mTBI screened approximately 1 year or more after
injury, 25% were found to have abnormal levels of one or more
anterior pituitary hormones (Stokes and Gallagher, 2011).
The Veteran groups in this study are highly similar in demo-
graphic characteristics and share the common experience of
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deployment under highly stressful and dangerous conditions
accentuated by extreme heat and the burden of heavy equipment
evenwhennot actively engaged in combat.Despite these common-
alities, the experience of blast trauma and the combat situations in
which these exposures occur have major long-term consequences
well beyond those of deployment to Iraq or Afghanistan. The con-
siderable overlap between the constellations of symptoms typical
of chronic hypopituitarism and persistent post-concussive symp-
toms (PPCS), in addition to the similarities of both to PTSD,
make accurate diagnosis of the etiology, progression, and identiﬁ-
able differences between the conditions of critical importance for
successful treatment, recovery, and rehabilitation (Masel, 2005).
The consequences of undiagnosed and untreated pituitary hor-
mone deﬁciencies aremanifold and signiﬁcant and include dimin-
ished QoL, cognitive deﬁciencies, fatigue, sleep disturbance, sexual
dysfunction, deleterious changes in metabolism and body com-
position, behavioral and psychiatric problems including anxiety,
irritability, social isolation, depression, and increased cardiovas-
cular mortality. PTHP, unlike PTSD and PPCS, is readily treatable
if correctly diagnosed, and many of its symptoms can be reversed
or ameliorated with appropriate hormone replacement therapy.
Several of the authors of previous studies of hypopituitarism
after TBI have advocated routine endocrine evaluation after brain
injury (Masel, 2004; Leal-Cerro et al., 2005; Schneider et al., 2005;
Urban et al., 2005; Powner et al., 2006; Behan and Agha, 2007;
Ho, 2007; Behan et al., 2008; Tanriverdi et al., 2008b, 2010b; Blair,
2010; Krahulik et al., 2010; Park et al., 2010). A recent review of the
literature (Guerrero and Alfonso, 2010) stated that because “many
of the symptoms of hypopituitarism are similar to those of TBI, it
is important to make clinicians caring for combat veterans aware
of its occurrence. . . All patients who had a TBI of any severity,
should undergo baseline hormonal evaluation.”
To our knowledge, this is the ﬁrst published study of basal
hormonal evaluation of combat Veterans with blast mTBI, and
our preliminary ﬁndings of PTHP in 42% of study participants
supports the advisability of routine screening for hypopituitarism
after brain injury in both military and civilian populations. Rou-
tine provocative testing for sAI and for GHD, the most frequently
observed chronic endocrine disorder resulting from TBI, is nei-
ther economically nor practically viable. However, measurement
of basal concentrations of a panel of pituitary and target-organ
hormones similar to those performed here may provide valuable
preliminary indications of those individuals most likely to bene-
ﬁt from further clinical evaluation. Similar preliminary screening
for pituitary dysfunction after blast concussion shows promise for
appropriately directing diagnostic and therapeutic decisions that
otherwise may remain unconsidered and for markedly facilitating
recovery and rehabilitation.
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